Latest News-I-Mab Mediaroom_Page

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-07-09 20:00 29861

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced ...

2021-07-01 20:00 13034

I-Mab Honored with Top Rankings by Institutional Investor

SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-06-30 20:00 12448

I-Mab Announces Upcoming Participation at July Conference

SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-06-29 20:00 8151

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB),...

2021-06-25 20:00 16170

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board

SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-06-21 20:00 7391

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmac...

2021-05-20 06:00 8163

I-Mab Added to MSCI China Index

SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-05-13 20:00 4955

I-Mab Announces Upcoming Participation at May Conferences

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-29 20:00 3236

I-Mab Filed 2020 Annual Report on Form 20-F

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-28 20:00 1517

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-26 19:00 1630

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

SHANGHAI and GAITHERSBURG, Md., March 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-03-03 21:00 5142

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-02-25 21:00 4677

Latest News

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab Honored with Top Rankings by Institutional Investor

I-Mab Announces Upcoming Participation at July Conference

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

I-Mab Added to MSCI China Index

I-Mab Announces Upcoming Participation at May Conferences

I-Mab Filed 2020 Annual Report on Form 20-F

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

I-Mab Announces Upcoming Participation at March Conferences

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer